-+ 0.00%
-+ 0.00%
-+ 0.00%

Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22

Benzinga·05/29/2026 12:33:08
Listen to the news
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Price Target of $22.